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Abstract
Objective—Describe the parent-reported prevalence of ADHD treatments among a national 
sample of children with special health care needs (CSHCN), and assess the alignment of ADHD 
treatment to current American Academy of Pediatrics (AAP) guidelines.
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Methods—Parent-reported data from the 2009–10 National Survey of Children with Special 
Health Care Needs allowed for weighted national and state-based prevalence estimates of 
medication, behavioral therapy, and dietary supplement use for ADHD treatment among CSHCN, 
aged 4–17 years with current ADHD. National estimates were compared across demographic 
groups, ADHD severity, and comorbidities. Medication treatment by drug class was described.
Results—Of CSHCN with current ADHD, 74.0% had past week medication treatment and 
44.0% had past year behavioral therapy. In the past year, 10.2% used dietary supplements for 
ADHD. Overall, 87.3% had received past week medication treatment or past year behavioral 
therapy (both=30.7%, neither=12.7%). Among preschool-aged CSHCN with ADHD, 25.4% 
received medication treatment alone, 31.9% received behavioral therapy alone, 21.2% received 
both treatments, and 21.4% received neither treatment. Central nervous system stimulants were the 
most common medication class (84.8%) among CSHCN with ADHD, followed by the selective 
norepinephrine reuptake inhibitor atomoxetine (8.4%).
Conclusions—These estimates benchmark clinical practice for the period directly preceding the 
AAP’s 2011 ADHD guidelines. Most children with ADHD received medication treatment or 
behavioral therapy; just under one-third received both. Multi-modal treatment was most common 
among CSHCN with severe ADHD and those with comorbidities. About half of preschoolers 
received behavioral therapy, the recommended first-line treatment for this age group.
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Introduction
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder (1) 
commonly managed by pediatricians.(2) Professional guidelines describe best practices for 
diagnosis (1) and treatment.(3, 4) The 2011 American Academy of Pediatrics’ (AAP) 
guidelines were expanded to include all children aged 4–18, with special considerations for 
preschoolers and adolescents. AAP now recommends behavioral therapy first for preschool-
aged children, with short-acting methylphenidate prescribed if therapy does not sufficiently 
improve symptoms. For older children, an FDA-approved ADHD medication with or 
without behavioral therapy is recommended.(5) In 2011, 6.4 million children aged 4–17 
years (11%) had a parent report of an ADHD diagnosis by a health care provider.(6) 
Prevalence estimates of parent-reported ADHD increased 33% from 1997 to 2008.(7) As 
ADHD diagnoses have increased, so has the prevalence of children taking medication for 
ADHD (medicated ADHD).(2, 8, 9) While there is earlier evidence of increased stimulant 
usage among preschoolers with ADHD (10), less is known on recent treatment patterns for 
very young children. Many children with ADHD not treated with medication receive 
behavioral or alternative therapies; however, little is known about the prevalence of these 
therapies. Epidemiological research suggests that families of black and Hispanic children 
with ADHD are less likely to choose pharmacological treatments and regard behavioral 
treatments more positively(11, 12); however, population-based data on the relative 
frequency of non-pharmacological ADHD treatment across racial and ethnic groups are 
needed to fully characterize ADHD treatment or identify potential treatment gaps.(6)
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The goals of this study were to: 1) describe the prevalence of medication, behavioral 
therapy, and dietary supplement use for ADHD among a national sample of children with 
special health care needs with ADHD; 2) identify differences in prevalence by relevant 
demographic factors; and 3) assess the alignment of treatment patterns to AAP’s age-group-
specific guidelines.(3)
Methods
The 2009–2010 National Survey of Children with Special Health Care Needs (NS-CSHCN) 
is a nationally representative, population-based telephone survey conducted by the Centers 
for Disease Control and Prevention with funding and direction from the Health Resources 
Services Administration; data were collected from July 2009 to March 2011.(13) A 
knowledgeable parent or guardian in the household responded to a 5-part screener to 
determine whether any children aged 2 to 17 years in the household met the criteria of 
having a special health care need. Children were considered to be CSHCN if they met one or 
more of the following criteria because of a medical, behavioral or other health condition that 
had lasted or was expected to last 12 or more months: needs or uses medicine other than 
vitamins prescribed by a doctor; needs or uses more medical care, mental health or 
educational services than is usual for most children of the same age; is limited or prevented 
in any way in his or her ability to do the things most children of the same age can do; needs 
or gets special therapy, such as physical, occupational or speech therapy; or has any kind of 
emotional, developmental or behavioral problem for which he or she needs treatment or 
counseling.(14) Nationally, 372,698 children were screened for a special health care need; of 
these, detailed interviews were completed regarding 40,242 CSHCN (1 randomly selected 
per eligible household). The overall response rate was 25.5%, which incorporates a 44% 
response rate among those contacted by landline and 15.2% among those contacted by 
cellphone. The interview completion rate among eligible families was 84% of landline 
households and 77% of cell phone families (81% overall).
The survey included questions on family demographics, health care services, and presence 
of selected health conditions, including ADHD. Parents were asked whether their child had 
ever been diagnosed with ADHD by a doctor or other health care provider, and if so, 
whether the child currently had ADHD. For those with current ADHD, follow-up questions 
assessed level of parent-reported severity (mild, moderate, or severe) and ADHD medication 
use during the past week and past year. Children completing the survey in the last five of six 
quarters were also asked a series of more specific ADHD treatment questions. If medication 
was used in the past week, the parent was asked to list medication(s) taken; because many 
respondents were at home during the telephone survey, they were asked to read the 
medication names directly from the medication bottles. Medications were grouped into six 
categories: central nervous system stimulants (CNS Stimulants), selective norepinephrine 
reuptake inhibitors (SNRI), selective serotonin reuptake inhibitors (SSRI), atypical 
antipsychotics, centrally acting alpha-agonist hypotensive agents, and centrally acting alpha-
adrenergic receptor agonists (Appendix; online). Parents were also asked whether their child 
had received “behavioral treatment for ADD or ADHD, including classroom management, 
peer interventions, social skills training, or cognitive-behavioral therapy” in the past year 
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and whether their child had taken dietary supplements to treat ADHD in the past week or 
past year.
Weighted analyses using SAS-callable SUDAAN (Version 11.0.0, RTI International, NC) 
were conducted to produce estimates of current ADHD prevalence among CSHCN aged 4–
17 years as well as prevalence of ADHD medication use overall and by medication class, 
behavioral therapy, and dietary supplement use to treat ADHD among CSHCN at the 
national and state level. National estimates of combination therapy (defined as past week 
medication treatment and past year behavioral therapy) were also described. National 
treatment estimates were compared using chi-square tests, stratified by child sex, child age, 
child race/ethnicity, US region of residence, health insurance status, presence of a medical 
home (a model of primary care that is patient-centered, comprehensive, team-based, 
coordinated, accessible, and focused on quality and safety),(15) parent-perception of ADHD 
severity, and presence of current co-occurring mental or developmental conditions (referred 
to as co-occurring conditions). Co-occurring conditions included in this analysis were 
depression, anxiety, behavioral or conduct problems (such as oppositional defiant disorder 
or conduct disorder), autism spectrum disorders, developmental delay, and intellectual 
disability. Multiple imputation was used by NCHS to create values for respondents with 
missing data on household income (7.9% missing), parental education (0.9%), race/ethnicity 
(0.7%), and household language (0.5%); imputed values were incorporated into the analyses 
for these variables.(13)
Results
Of all completed NS-CSHCN interviews (40,242), 9,459 CSHCN aged 4–17 years were 
reported to have current ADHD, had valid responses to the ADHD treatment questions, and 
had complete data on sex. The demographic profile of the sample and this population is 
shown in Table 1; online. Among all CSHCN, the weighted estimate of parent-reported 
current ADHD was 32.3% (CI: 31.5–33.2).
Medication Treatment
Of the CSHCN reported by their parents to have current ADHD, 82.6% (CI: 81.1—84.1) 
had taken medication for ADHD in the past year and 74.0% (CI: 72.3—75.7) had taken 
medication for ADHD in the past week. Young CSHCN 4–5 years old with current ADHD 
were least likely to have taken medication in the past week. A larger percentage of boys had 
taken medication in the past week compared to girls, although this difference did not reach 
statistical significance (p=0.06; Table 2). CSHCN who were uninsured, without a medical 
home, lived in the West, with mild ADHD, or with a co-occurring condition were less likely 
to have taken medication in the past week (Table 2; Figure 1). Compared to non-Hispanic 
white CSHCN, CSHCN of other racial and ethnic groups were less likely to have taken 
medication for ADHD in the past week. State-level prevalence of current medication 
treatment among CSHCN with ADHD ranged from 56.6% (California) to 87.5% (Michigan; 
Figure 1).
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Past Year Behavioral Therapy
Among CSHCN with current ADHD, 44.0% (CI: 42.2—45.8) had received behavioral 
therapy in the past year. CSHCN with ADHD who were 12 years of age or older were less 
likely than the youngest children (4–5 years of age) to have received behavioral therapy in 
the previous year. CSHCN with current ADHD living below the federal poverty level were 
more likely to receive behavioral therapy than those above 200% of the federal poverty 
level. Other groups more likely to have received behavioral therapy included those that had 
public insurance (relative to non-public insurance), did not have a medical home, and had 
moderate or severe ADHD (compared to mild ADHD) (Table 2; Figure 2). Behavioral 
therapy in the past year was less common among non-Hispanic white CSHCN compared to 
other racial/ethnic groups and was less common in the South than in the West. CSHCN with 
ADHD and a co-occurring condition were twice as likely as those without a co-occurring 
condition to have had behavioral therapy in the past year. State-level prevalence of 
behavioral therapy in the past year among CSHCN with ADHD ranged from 32.5% 
(Tennessee) to 60.6% (Hawaii; Figure 2). There was an inverse correlation between the 
state-based estimates of past year behavioral therapy and past week medication for ADHD 
(r= −0.399, p <0.01).
Dietary Supplement Use
Of CSHCN with current ADHD, 10.2% (CI: 9.2—11.4) took dietary supplements for 
ADHD in the past year; 6.4% (CI: 5.6—7.4) in the past week. CSHCN with ADHD who 
lived in the Midwest (compared to the West) or were 12 years of age or older (compared to 
those 4–5 years) were less likely to have taken dietary supplements within the past year. 
Those who did not have a medical home and those with a co-occurring condition were more 
likely to have received dietary supplements within the past year (Table 2). Dietary 
supplement use was less common among those whose parents were high school graduates 
(compared to those who had more than a HS education), with household incomes below 
100% of the federal poverty level (compared to those with a FPL over 200%), and had 
public insurance (relative to non-public insurance). State-level estimates of dietary 
supplement usage in the past year among CSHCN with ADHD ranged from 3.7% (Missouri) 
to 18.1% (Montana; Figure 3; online).
Combination Therapy
Overall, 30.7% (CI: 29.1—32.4) of CSHCN with current ADHD were receiving both 
medication and behavioral therapy for ADHD (Table 3). The percentage of CSHCN 
receiving either or both medication treatment or behavioral therapy to treat ADHD was 
87.3% (CI: 85.9—88.6); an additional 1.2% (CI: 0.9—1.6) were taking dietary supplements 
alone for ADHD treatment, such that 88.6% (CI: 87.2—89.8) of CSHCN with ADHD were 
receiving one or more of the three therapies. Of the potential combinations of medication 
and behavioral therapy, medication treatment alone was the most common current treatment 
modality overall and for most demographic subgroups (Table 3). Nearly half (43.3%) of 
CSHCN with ADHD in the following demographic groups were receiving medication 
treatment without behavioral therapy: non-Hispanic white CSHCN, CSHCN living in the 
Midwest or South, CSHCN with non-public health insurance, and CSHCN with mild 
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ADHD; over half of CSHCN with a medical home or without a co-occurring condition were 
receiving medication without behavioral therapy.
Descriptively, the CSHCN subgroups that had the highest rates of medication and 
behavioral therapy were those in the Northeast, with public insurance, with severe ADHD, 
and with a co-occurring condition (Table 3). The CSHCN subgroups with the highest rates 
of neither ADHD medication treatment nor behavioral therapy were children who were 
aged 4–5, of other races, spoke a primary language other than English, lived in the West, did 
not have health insurance, and had mild ADHD. There was not a statistically significant 
difference in treatment modalities between boys and girls.
Of CSHCN who were receiving both medication treatment and behavioral therapy, 14.2% 
(95% CI: 12.1%—16.5%) were also taking dietary supplements. Among CSHCN receiving 
medication but not behavioral therapy, 5.1% (95% CI: 4.1%—6.4%) also took dietary 
supplements, while 18.4% (95% CI: 14.4%—23.3%) of CSHCN receiving behavioral 
therapy but not medication took dietary supplements. Overall, 9.3% (95% CI: 6.9%—
12.5%) of CSHCN who received neither medication nor behavioral therapy were taking 
dietary supplements.
Among CSHCN aged 4–5, 25.4% (95% CI: 17.4—35.5) were receiving medication 
treatment alone, 31.9% (95% CI: 23.5—41.8) were receiving behavioral therapy alone, and 
21.2% (95% CI: 15.1—29.1) were receiving both treatments (Table 3). The remaining 
21.4% (95% CI: 13.5—32.4) of CSHCN aged 4–5 received neither behavioral therapy nor 
medication.
Medication Treatment by Medication Class
Of CSHCN with ADHD who took medication for ADHD in the past week, 84.8% (CI: 83.3
—86.3) took a central nervous system stimulant (CNSS) medication; a little more than half 
of these being methylphenidate formulations (55.8%; CI: 53.6—58.0). Of all CSHCN taking 
medication for ADHD, 47.3% (CI: 45.3—49.4) took methylphenidate formulations. The 
second most commonly reported medication class was selective norepinephrine reuptake 
inhibitors (SNRI), for the use of the SNRI atomoxetine, which was reported for 8.4% (CI: 
7.4—9.6) of CSHCN who were taking medication for ADHD. A smaller proportion of 
children were taking medication from each of four other drug classes reported for the 
treatment of ADHD (atypical antipsychotics: 5.7%, CI: 4.7—6.8; SSRIs: 3.1%, CI: 2.4—
4.0; centrally-acting alpha-agonist hypotensive agents (Clonidine): 4.1%, CI: 3.3—5.0; and 
centrally acting alpha-adrenergic receptor agonists (Guanfacine): 4.3%, CI: 3.6—5.2).
Discussion
This study establishes the relative national prevalence of reported ADHD treatments, 
specifically medication treatment and behavioral therapy, as well as the use of dietary 
supplements for the treatment of ADHD among US CSHCN in 2009–10. In this national 
sample of CSHCN, approximately 87% of children with parent-reported current ADHD 
were receiving either medication treatment or behavioral therapy, with an additional 1.2% 
receiving dietary supplements alone as an alternative treatment. Medication treatment alone 
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was the most common treatment for ADHD, with nearly half of CSHCN with current 
ADHD taking medication alone for treatment. The most common drug class of ADHD 
medications was CNSS, with nearly 85% taking a medication in this drug class. The inverse 
relationship observed between state-level medication and behavioral treatment estimates 
informs previous discussions about the geographic variability in ADHD medication 
treatment (6, 16–18) and suggests that states that have lower state-wide estimates of 
behavioral therapy tend to have higher estimates of medication treatment.
ADHD treatment results in important and measurable improvements in the core symptoms 
of ADHD, with published effect sizes ranging from 0.6 for behavioral strategies and 0.7 for 
non-stimulant medications to 1.0 for stimulant medications.(3) In this study, just under one-
third of CSHCN with ADHD were receiving both medication and behavioral therapy for 
ADHD. Children with severe ADHD and those with comorbidities were among the most 
likely to receive combination treatment. However, 56.0% of CSHCN had not received 
behavioral therapy in the past year. This is an important finding, given previous research 
suggesting the benefits of multi-modal (medication plus behavioral therapy) treatment for 
childhood ADHD on core and peripheral features of the disorder and AAP’s 
recommendation of combination therapy for children 6–11 years of age.(3, 19–21) Future 
research is warranted that investigates barriers to receipt of behavioral therapies for ADHD, 
including a lack of access due to eligibility requirements, lack of availability in the 
geographic area, or cost barriers (including insurance coverage).
This study revealed that non-Hispanic white CSHCN were more likely to receive medication 
treatment for ADHD, whereas CSHCN of all other races and ethnicities were more likely to 
receive behavioral therapy for ADHD, while rates of combination therapy (medication and 
behavioral therapy) were similar across racial groups. These findings are consistent with 
research suggesting more favorable perceptions of behavioral therapy and less favorable 
views of medications among black and Hispanic parents as compared to white parents.(22) 
Approximately one in five CSHCN of “other” races and children who were reported to 
speak a primary language other than English were neither receiving medication nor 
behavioral therapy for ADHD, representing a potential service gap.
For preschool-aged (4–5 years) CSHCN with an ADHD diagnosis the prevalence rates of 
each of the four treatment groups (medication alone, medication plus behavioral therapy, 
behavioral therapy alone, and neither behavioral nor medication treatment) were similar. 
Although recommended as a first-line treatment for ADHD,(3) half (53.2%) of preschool-
aged CSHCN with ADHD received behavioral therapy in the past year. These data provide 
an important benchmark for clinical practice, as these data were collected in the years just 
before the release of the 2011 AAP diagnostic and treatment guidelines for ADHD.(5) AAP 
guidelines currently recommend that behavioral therapy should be used as first-line 
treatment for ADHD among preschoolers, with methylphenidate prescribed when persistent, 
significant functional impairment persists. A recent comparative effectiveness study 
identified four behavioral interventions for preschool-aged children with ADHD,(23) but 
these and other high quality interventions may not be available to children in medically 
underserved settings in which there is limited access. Ongoing surveillance and future 
research that studies ADHD practice patterns for preschoolers can contribute to 
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understanding the barriers to the provision of behavioral services, which may currently limit 
clinical practice from being more closely aligned with best practices.
Strengths of this study include analysis of a large, nationally representative sample of 
CSHCN; collection of ADHD medication treatment by asking parents to read the name of 
the medication directly from available prescription bottles, thereby reducing recall bias; and 
concurrent collection of medication treatment, behavioral therapy, and dietary supplement 
use for ADHD treatment. However, the results should be considered within the context of 
certain limitations. The analyses were based on parent-reported data that were not clinically 
validated. As previously reported, the vast majority of children with ADHD meet CSHCN 
criteria (14), however approximately 13% of children with ADHD do not meet the criteria 
(24) and are therefore not represented by these data; included children with ADHD who met 
CSHCN criteria may be more impaired and could have different treatment patterns than 
children with ADHD who do not meet CSHCN criteria. The behavioral therapy question 
was somewhat broad, asking about “behavioral treatment for ADHD, such as classroom 
management, peer interventions, social skills training, or cognitive-behavioral therapy”; the 
data did not lend itself to differentiating treatment intensity or treatment quality and low 
intensity school-based interventions were therefore counted with intensive multi-month, 
structured behavioral therapy programs. Further, some children were likely receiving other 
treatments for ADHD that were not included in the survey (e.g., neurofeedback); therefore, 
the total prevalence of any treatment for ADHD is likely underestimated. Finally, the 
response rates of the NS-CSHCN (landline: 43.7%, cell-phone: 15.2%, combined: 25.5%) 
were low and could have led to biased results, despite the fact that weighting accounted for 
non-response.
This study represents the first nationally-representative US study to estimate behavioral 
treatment and dietary supplement use for the treatment of ADHD, alongside estimates of 
medication for ADHD treatment. The relative percentages reveal that ADHD medication 
was the most common single ADHD treatment in 2009–10, followed by combination 
therapy (medication and behavioral therapy), and then behavioral therapy alone. Future 
research can help improve understanding of the barriers to the provision of behavioral 
therapy for childhood ADHD, particularly among the preschool population.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
Funding Source:
None other than salaries at the authors’ home institutions.
Abbreviations
ADHD attention-deficit/hyperactivity disorder
Visser et al. Page 8













CSHCN children with special health care needs
References
1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5. 
American Psychiatric Publishing; 2013. 
2. McDonald DC, Jalbert SK. Geographic Variation and Disparity in Stimulant Treatment of Adults 
and Children in the United States in 2008. Psychiatric Services. 2013 Nov 1; 64(11):1079–86. Epub 
2013/08/06. Eng. [PubMed: 23912601] 
3. American Academy of Pediatrics. ADHD: Clinical practice guideline for the diagnosis, evaluation, 
and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 
2011; 128:1007–22. [PubMed: 22003063] 
4. American Academy of Child and Adolescent Psychiatry. Practice parameter for the assessment and 
treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child 
Adolesc Psychiatry. 2007; 46:894–921. [PubMed: 17581453] 
5. Wolraich M, Brown L, Brown RT, DuPaul G, Earls M, et al. American Academy of Pediatrics’ 
Subcommittee on Attention-Deficit/Hyperactivity Disorder Steering Committee on Quality 
Improvement and Management. ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, 
and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics 
2011. Nov 1.2011 128:1007–22.
6. Visser SN, Danielson ML, Bitsko RH, Holbrook JR, Kogan MD, Ghandour RM, et al. Trends in the 
Parent-Report of Health Care Provider-Diagnosed and Medicated Attention-Deficit/Hyperactivity 
Disorder: United States, 2003–2011. J Am Acad Child Adolesc Psychiatry. 2014; 53:34–46.e2. 
[PubMed: 24342384] 
7. Boyle CA, Boulet S, Schieve LA, Cohen RA, Blumberg SJ, Yeargin-Allsopp M, et al. Trends in the 
prevalence of developmental disabilities in US children, 1997–2008. Pediatrics. 2011; 127:1034–42. 
[PubMed: 21606152] 
8. Centers for Disease Control and Prevention. Increasing prevalence of parent-reported attention-
deficit/hyperactivity disorder among children — United States, 2003 and 2007. MMWR Morb 
Mortal Wkly Rep. 2010; 59:1439–43. [PubMed: 21063274] 
9. Zuvekas SH, Vitiello B. Stimulant medication use in children: A 12-year perspective. Am J 
Psychiatry. 2012; 169:160–6. [PubMed: 22420039] 
10. Zito JM, Safer DJ, dosReis S, Gardner JF, Boles M, Lynch F. Trends in the prescribing of 
psychotropic medications to preschoolers. Jama. 2000 Feb 23.283:1025–30. [PubMed: 10697062] 
11. Stevens J, Harman JS, Kelleher KJ. Ethnic and regional differences in primary care visits for 
Attention-Deficit Hyperactivity Disorder. Journal of Developmental & Behavioral Pediatrics. 
2004; 25:318–25. [PubMed: 15502548] 
12. Pham AV, Carlson JS, Kosciulek JF. Ethnic Differences in Parental Beliefs of Attention-Deficit/
Hyperactivity Disorder and Treatment. Journal of Attention Disorders 2010. May 1.2010 13:584–
91.
13. Centers for Disease Control and Prevention National Center for Health Statistics State and Local 
Area Integrated Telephone Survey. 2009–2010 National Survey of Children with Special Health 
Care Needs Frequently Asked Questions. 2011. [updated December 2011]. Available from: http://
www.cdc.gov/nchs/slaits/cshcn.htm
14. Bethell CD, Read D, Stein RE, Blumberg SJ, Wells N, Newacheck PW. Identifying children with 
special health care needs: development and evaluation of a short screening instrument. Ambul 
Pediatr. 2002 Jan-Feb;2:38–48. Epub 2002/03/13. eng. [PubMed: 11888437] 
15. American Academy of Family Physicians (AAFP), American Academy of Pediatrics (AAP), 
American College of Physicians (ACP), American Osteopathic Association (AOA). Joint 
Principles of the Patient Centered Medical Home. 2007 Feb. 
Visser et al. Page 9













16. Visser SN, Blumberg SJ, Danielson ML, Bitsko RH, Kogan MD. State-based and demographic 
variation in parent-reported ADHD medication rates, 2007–2008. Preventing Chronic Disease. 
2013; 10:20073.
17. Fulton BD, Scheffler RM, Hinshaw SP, Levine P, Stone S, Brown TT, et al. National variation of 
ADHD diagnostic prevalence and medication use: Health care providers and education policies. 
Psychiatric Services. 2009; 60:1075–83. [PubMed: 19648195] 
18. Arns M, van der Heijden KB, Arnold LE, Kenemans JL. Geographic Variation in the Prevalence of 
Attention-Deficit/Hyperactivity Disorder: The Sunny Perspective. Biological psychiatry. 2013 Oct 
15.74:585–90. [PubMed: 23523340] 
19. Multimodal Treatment Study of Children with ADHD Cooperative Group. A 14-month 
randomized clinical trial of treatment strategies for Attention Deficit Hyperactivity Disorder. 
Archives of General Psychiatry. 1999 Dec.56:1073–86. [PubMed: 10591283] 
20. Pelham WE, Gnagy EM. Psychosocial and combined treatments for ADHD. Mental Retardation 
and Developmental Disabilities Research Reviews. 1999; 5:225–36.
21. Majewicz-Hefley A, Carlson JS. A Meta-Analysis of Combined Treatments for Children 
Diagnosed With ADHD. Journal of Attention Disorders 2007. Feb 1.2007 10:239–50.
22. Pham AV, Carlson JS, Kosciulek JF. Ethnic differences in parental beliefs of attention-deficit/
hyperactivity disorder and treatment. J Atten Disord. 2010 May.13:584–91. Epub 2009/05/06. eng. 
[PubMed: 19414623] 
23. Charach, A.; Dashti, B.; Carson, P.; Booker, L.; Lim, CG.; Lillie, E., et al. Attention Deficit 
Hyperactivity Disorder: Effectiveness of Treatment in At-Risk Preschoolers; Long-Term 
Effectiveness in All Ages; and Variability in Prevalence, Diagnosis, and Treatment. Rockville, 
MD: Agency for Healthcare Research and Quality; 2011. 
24. Visser, SN.; Danielson, ML.; Ghandour, RM. Frequency of medication treatment, behavioral 
therapy, and dietary supplements among a national sample of children with special health care 
needs with ADHD. American Public Health Association Annual Meeting; October 29, 2012; San 
Francisco, CA. 2012. 
Appendix. Categories of medications taken in past week to treat attention-
deficit/hyperactivity disorder (ADHD) by parent report, National Survey of 
Children with Special Health Care Needs: 2009–10
Drug Class* Medications Included^
Central nervous system stimulants (CNS 
Stimulants)
Adderall, Adderall XR, Amphetamine
Concerta
Daytrana Patch






Ritalin, Ritalin LA, Ritalin SR
Vyvanse, Lisdexamfetmine
Selective norepinephrine reuptake inhibitors 
(SNRI)
Strattera, Atomoxetine







Centrally acting alpha-agonist hypotensive agents Clonidine
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Drug Class* Medications Included^




Drug class was determined from http://www.nlm.nih.gov/medlineplus/medlineplus.html
^
Seroquel, Trazadone, and Wellbutrin were reported by a small number of families, but were excluded from analyses due 
to low sample size.
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Parent-reported ADHD medication use in the past week among children (4–17 years) with 
special health care needs and ADHD: US, 2009–10
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Parent-reported behavioral therapy for ADHD in the past year among children (4–17 years) 
with special health care needs and ADHD: US, 2009–10
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Parent-reported dietary supplement use for ADHD in the past year among children (4–17 
years) with special health care needs and ADHD: US, 2009–10
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Table 1
Characteristics of children with special health care needs aged 4–17 who currently have attention-deficit/
hyperactivity disorder (ADHD) by parent report, National Survey of Children with Special Health Care 
Needs: US, 2009–10
Unweighted n Weighted % 95% CI
Boys 6,769 69.8 (68.1, 71.5)
Girls 2,690 30.2 (28.5, 31.9)
Age 4–5 280 3.4 (2.8, 4.1)
Age 6–11 4235 45.1 (43.3, 46.9)
Age 12–17 4944 51.5 (49.7, 53.3)
Non-Hispanic White, single race1 6,845 64.9 (63.0, 66.7)
Non-Hispanic Black, single race1 896 15.1 (13.7, 16.6)
Hispanic, any race(s)1 871 12.9 (11.5, 14.5)
Non-Hispanic other single race or multiple races1 847 7.1 (6.2, 8.2)
Highest education of a resident parent
 Less Than High School1 575 12.3 (10.8, 13.8)
 High School Graduate1 1,680 22.4 (20.9, 24.0)
 More Than High School1 7,204 65.3 (63.5, 67.1)
% Federal Poverty Level
 <100% 1 1,896 25.0 (23.4, 26.6)
 100%–200%1 1,955 22.6 (21.1, 24.2)
 >200%1 5,608 52.5 (50.6, 54.3)
English as Primary Household Language1 9,292 96.9 (95.9, 97.6)
Other Language As Primary1 167 3.1 (2.4, 4.1)
Region of U.S.
 Northeast 1,614 17.0 (15.8, 18.3)
 Midwest 2,191 23.0 (21.8, 24.4)
 South 3,572 43.4 (41.8, 45.1)
 West 2,082 16.6 (15.2, 18.1)
Type of Health Insurance
 Non-Public Insurance 5,263 48.7 (46.9, 50.5)
 Public Insurance 3,937 48.6 (46.8, 50.4)
 No Insurance 247 2.7 (2.2, 3.3)
Medical Home 3,836 38.5 (36.8, 40.3)
No Medical Home 5,344 61.5 (59.7, 63.2)
Parent-Reported ADHD Severity
 Mild 3,420 33.7 (32.1, 35.4)
 Moderate 4,279 45.2 (43.4, 47.0)
 Severe 1,719 21.1 (19.6, 22.7)
Any Co-occurring Conditions2 5,381 59.4 (57.7, 61.2)
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Unweighted n Weighted % 95% CI
No Co-occurring Condition 4,013 40.6 (38.8, 42.3)
1
Multiple imputation used to estimate value for respondents with missing data on household income (7.9% missing), parental education (0.9%), 
race/ethnicity (0.7%), and household language (0.5%).
2
Co-occurring conditions included parent-reported depression, anxiety, behavioral or conduct problems (such as oppositional defiant disorder or 
conduct disorder), autism spectrum disorder, developmental delay and intellectual disability.
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